Anesiva Announces Publication Of Phase 3 Zingo(TM) Data In The Journal Pediatrics
Anesiva, Inc. (Nasdaq: ANSV) announced the publication of data in Pediatrics, the journal of the American Academy of Pediatrics, from a Phase 3 trial of Zingo(TM) (lidocaine hydrochloride monohydrate) powder intradermal injection, the company’s fast-acting, topical, needle-free local anesthetic, that showed treatment with Zingo was associated with significantly less pain during intravenous (IV) line placement or venipuncture as compared to sham placebo.
More: continued here
Filed under: Pain / Anesthetics on May 15th, 2008